Detection of Tumor DNA in Blood Samples From Cancer Patients

Status:	Recruiting
Conditions:	Cancer, Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	8/10/2018
Start Date:	December 2014
End Date:	November 2020
Contact:	Haluk Tezcan, MD
Email:	htezcan@lexentbio.com
Phone:	530-863-7922

Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and "Healthy Controls"

The aim of this study is to employ genomic detection methodologies to measure the relative
amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic
disease that is either commencing, currently undergoing or completed cytotoxic chemotherapy
treatment. More generally, this approach will allow us to develop a quantitative measure of
therapy efficacy via the counting of the relative changes in tumor molecules over the course
of treatment.

Inclusion Criteria:

- Age 18 years or older

- Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas,
ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or
neoadjuvant therapy followed by surgery

- Starting treatment or a new line of treatment

- Able to understand and grant informed consent

- Able to have their blood drawn

Exclusion Criteria:

- Unable to grant informed consent or comply with all study procedures.

- Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia

We found this trial at

sites

Sharp Clinical Oncology Research

San Diego, California 92123

Principal Investigator: Shieh Marie, MD

Phone: 858-939-5062

from

San Diego, CA